8-K: 10x Genomics Announces Q2 2024 Results, CFO Transition, and Commercial Leadership Changes

10x Genomics reported a 4% revenue increase for Q2 2024, a CFO transition, and a new Chief Commercial Officer.

Summary

• 10x Genomics reported a revenue of $153.1 million for the second quarter of 2024, a 4% increase compared to $146.8 million in the same period last year.
• The revenue growth was primarily driven by stronger sales of consumables.
• Gross margin remained flat year-over-year at 68%.
• Operating expenses decreased by 10% to $146.0 million, down from $163.0 million in the prior year, due to lower personnel costs and reduced laboratory expenses.
• The operating loss improved to $41.7 million, compared to $63.4 million in the same quarter of the previous year.
• Net loss also improved to $37.9 million, compared to a net loss of $62.4 million in the second quarter of 2023.
• The company's cash and cash equivalents and marketable securities totaled $380.1 million as of June 30, 2024.
• 10x Genomics updated its full-year 2024 revenue guidance to a range of $640 million to $660 million, down from the previous range of $670 million to $690 million.
• This updated guidance represents a 3% to 7% growth over the full year 2023 revenue.
• Adam Taich will join as Chief Financial Officer on August 12, 2024, replacing Justin McAnear, who is resigning effective August 30, 2024.
• Mennah Moustafa has been appointed Chief Commercial Officer, effective August 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to improved financial results and new product launches, but tempered by the lowered revenue guidance and CFO transition.

Positives

• Revenue increased by 4% year-over-year, driven by strong consumables sales.
• Operating expenses decreased by 10%, leading to a significant reduction in operating loss.
• Net loss improved substantially compared to the same quarter last year.
• The company launched new products, including Xenium Prime 5K, and secured a major project with the Garvan Institute.
• The company has a strong cash position with $380.1 million in cash and marketable securities.
• The appointment of a new CFO and CCO is expected to strengthen the leadership team.

Negatives

• The company lowered its full-year 2024 revenue guidance from $670-$690 million to $640-$660 million.
• The company is still operating at a loss, although the loss has decreased compared to the previous year.
• The CFO is resigning, which may cause some disruption.

Risks

• The company faces a challenging macro environment, which could impact future sales.
• The updated revenue guidance indicates a potential slowdown in growth.
• The CFO transition could create uncertainty and potential disruption.
• The company's future performance is subject to risks and uncertainties detailed in their SEC filings.

Future Outlook

10x Genomics updated its full-year 2024 revenue guidance to a range of $640 million to $660 million, representing 3% to 7% growth over 2023 revenue. The company remains confident in the long-term potential of its platforms.

Management Comments

• Serge Saxonov, CEO, stated that the company saw strong demand for spatial and single cell consumables this quarter, fueled by significant product launches earlier this year.
• Serge Saxonov also mentioned that the company is evolving its commercial organization and continuing to execute its strategy.
• Justin McAnear expressed pride in the company's growth and accomplishments during his tenure.
• Mennah Moustafa is excited to build a high-performance commercial organization.
• Adam Taich believes 10x is one of the most exciting companies in the industry and is thrilled to drive the next phase of growth.

Industry Context

The announcement reflects the ongoing growth and competition in the single-cell and spatial biology market. 10x Genomics is positioning itself to capitalize on the increasing demand for advanced research tools in this field. The leadership changes suggest a strategic shift towards strengthening commercial operations and financial management.

Comparison to Industry Standards

• While 10x Genomics experienced a 4% revenue increase, other life science companies such as Illumina and Thermo Fisher Scientific have reported varying growth rates in their respective sectors, with some experiencing higher growth in specific areas like bioprocessing and diagnostics.
• The gross margin of 68% is relatively consistent with other life science tool companies, but some may have higher margins due to different product mixes and cost structures.
• The reduction in operating expenses by 10% is a positive sign, as many companies in the sector are focusing on cost management to improve profitability.
• The updated revenue guidance of 3-7% growth is lower than some analysts' expectations for the sector, which may be influenced by the broader economic environment and specific market dynamics.
• The appointment of a new CFO with experience at Thermo Fisher Scientific and other companies suggests a focus on operational efficiency and strategic financial planning, which is a common theme among successful life science companies.

Management Changes

Stakeholder Impact

• Shareholders may react to the lowered revenue guidance and CFO transition.
• Employees may experience changes due to the new leadership.
• Customers may benefit from the new product launches and improved commercial strategy.
• Suppliers may see changes in demand based on the company's updated outlook.

Next Steps

• 10x Genomics will host a conference call to discuss the second quarter 2024 financial results, business developments and outlook.
• The company will focus on integrating the new CFO and CCO into their roles.
• The company will continue to execute its strategy and evolve its commercial organization.

Key Dates

Keywords

10x Genomics, Financial Results, Q2 2024, Chief Financial Officer, Chief Commercial Officer, Revenue, Operating Loss, Net Loss, Consumables, Xenium Prime 5K, Chromium GEM-X, Single Cell Biology, Spatial Biology